UPDATE: Jefferies Raises PT to $25 on Abiomed

Jefferies reiterates its Buy rating on Abiomed (NASDAQ: ABMD) and raises its price target by $1 to $25 a share as the company is poised to meet its seemingly lofty guidance following consecutive quarterly profitability.

Jefferies notes, "ABMD reported F3Q results ahead of forecasts and delivered a second consecutive Q of profitability on strong Impella adoption. With the full PII data set and economic benefit analysis, recent inclusion into clinical guidelines, and possible expedited Japan approval, the Impella run is just starting."

ABMD closed at $20.98 a share on Friday.